Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19.56% stake in the company

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/18/2019 | 01:05am EST

Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19.56% stake in the company

Dublin, Ireland - October 18, 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that it has concluded a licensing agreement for Aemcolo™ for the USA and a simultaneous share subscription agreement with RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL).

Aemcolo™ is Cosmo's recently FDA approved antibiotic for the treatment of Travelers' Diarrhea and is also in Phase II clinical trials for IBS-D.

RedHill Biopharma is focused on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases. RedHill already commercializes gastrointestinal products in the U.S. and currently has a sales force of approximately 40 sales representatives, which it plans to further expand to approximately 140 sales representatives assuming approval of its drug RHB-105 (Talicia) for the treatment of H. pylori infection. RHB-105's PDUFA date is set for November 2, 2019.

The license agreement provides for high twenty percent royalties and potential regulatory and commercial cash milestones totalling up to USD 100m, plus a USD 12m down-payment in RedHill ADSs (American Depositary Shares listed on NASDAQ). Cosmo will be the exclusive supplier of Aemcolo™.

The share subscription agreement provides for an investment of USD 36.3m in RedHill ADSs at a price equal to the last 30-day average. Together with the ADSs received as down-payment, Cosmo will hold an overall stake in the company of 19.56% and will become the largest shareholder in RedHill. Cosmo will be entitled to appoint one board member of RedHill.

Mauro Ajani, Chairman of Cosmo, said: "This deal is another big step in the transformation of Cosmo and it is closer to our history. After the deals with Medtronic, where we partnered AI and Eleview, we have now found the right US partner for Aemcolo™. We are most pleased to become RedHill's largest shareholder: this stake is strategic and a demonstration of trust. We look forward to contributing towards making RedHill a rousing success."

Alessandro Della Chà, CEO of Cosmo, said: "After having received several offers, we believe we have found in RedHill the features for a long and successful collaboration: a strong and expert management team with a history of commercial success, a very interesting pipeline, a company size where our contribution could make a substantial difference and the opportunity of an equity for product deal. We are very happy to start this new partnership".

"Cosmo is a world leader in optimized therapies for gastrointestinal diseases with a strong track record of success, expertise and commitment to changing the treatment landscape for patients", said Dror Ben-Asher, RedHill's CEO. "The strategic partnership with Cosmo is an important validation of RedHill's commercial capabilities, promising late-stage pipeline and overall strategy to become a leading gastrointestinal-focused company in the US. Cosmo's investment in RedHill ahead of the potential FDA approval and if approved by the FDA, the launch of RHB-105 (Talicia) and the addition of Aemcolo® to our GI product portfolio positions us well for the future. We are proud to have Cosmo as our partner and look forward to a successful strategic collaboration."




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COSMO PHARMACEUTICALS N.V.
12/02COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
AQ
12/02Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
TE
11/26COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
PU
11/26Cosmo appoints New CSO as current CSO retires
TE
11/05Cosmo's Partner RedHill announces approval of Talicia for the treatment of H...
AQ
11/04Cosmo's Partner RedHill gibt die Zulassung von Talicia® für die Behandlung vo..
TE
11/04Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H..
TE
10/21Cosmo licenses Aemcolo for the USA to RedHill Biopharma and takes a 19.56% st..
AQ
10/21RedHill Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals a..
AQ
10/18Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19..
TE
More news
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,4 M
Net income 2019 -27,6 M
Finance 2019 117 M
Yield 2019 -
P/E ratio 2019 -36,8x
P/E ratio 2020 -92,8x
EV / Sales2019 18,5x
EV / Sales2020 9,85x
Capitalization 991 M
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 101,86  €
Last Close Price 67,76  €
Spread / Highest target 101%
Spread / Average Target 50,3%
Spread / Lowest Target 4,52%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.-17.86%1 108
JOHNSON & JOHNSON8.48%371 041
ROCHE HOLDING AG24.45%262 849
MERCK AND COMPANY16.45%226 542
PFIZER-12.44%211 514
NOVARTIS22.84%209 840